Biovie is trading 5.4% up at $1.81, as U.S. stocks rally following the Federal Reserve’s September 16 rate decision.

  • The S&P 500 is up 0.96%, while the Nasdaq Composite is up 1.24%.
  • No fresh company-specific catalyst was identified for September 17; the move appears mainly driven by improved broader-market sentiment after the previous session’s selloff.
  • Investors continue weighing the disappointing ADDRESS-LC trial results reported September 15.